Enlivex Ltd.

Stage 4 · Declining · week 27

As of Oct 22, 2026, Enlivex is in Stage 4, the downtrend phase, now in week 27 (since Apr 16, 2026). It closed at $0.20, 98.9% below its 52-week high and below its 200-day average, which is falling.

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. More about the company

$0.20

-8.13% today

$4.0M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ENLV early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 17w

S4 31w

S4 15w

S4 27w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 17w → S1 6w → S2 12w → S3 5w → S4 17w → S1 8w → S4 31w → S1 5w → S2 6w → S3 5w → S4 15w → S1 7w → S2 2w → S1 1w → S4 27w current

Total tracked: 165 weeks across 15 stage runs.

ENLV among Biotechnology545th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…545	ENLVEnlivex Ltd.	Stage 4 · wk 27	3	−68.9%

vs 52W High

-98.9%

$0.20 lo$18.15 hi

98.9% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 27

1w13w26w

Week 27, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-97.8%

200 DMA: $9.11 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.38x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-68.9%

-95.3%

-98.5%

YTD

-98.2%

-98.8%

Scan Membership

Breakout Watch

Latest: 2024-01-29

4 appearances in last 60 days. First seen: 2019-04-04.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 27 · Vol 0.38x

2026-10-21S4

Wk 27 · Vol 0.61x

2026-10-20S4

Wk 26 · Vol 0.37x

2026-10-19S4

Wk 26 · Vol 0.51x

2026-10-16S4

Wk 26 · Vol 0.41x

2026-10-15S4

Wk 26 · Vol 0.47x

2026-10-14S4

Wk 26 · Vol 0.47x

2026-10-13S4

Wk 25 · Vol 0.75x

2026-10-12S4

Wk 25 · Vol 0.77x

2026-10-09S4

Wk 25 · Vol 2.52x

2026-10-08S4

Wk 25 · Vol 71.40x

2026-10-07S4

Wk 25 · Vol 8.47x

Moving averages & range

50 DMA

$0.83

200 DMA

$9.11

52W High

$18.15

52W Low

$0.20

5D Low

$0.20

Resistance levels (recent highs)

20d High

$0.60

60d High

$2.18

120d High

$12.95

250d High

$18.15

Next resistance

+200.5%

to 20d High

P/E (TTM)

0.0

Forward -0.3

ROE

+162.9%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.0

Enlivex: quick answers

What stage is Enlivex in?

As of Oct 22, 2026, Enlivex (ENLV) is in Stage 4, the downtrend phase. It entered Stage 4 on Apr 16, 2026 and is in week 27. What the four stages mean

Is Enlivex in an uptrend?

No. Enlivex is in a Stage 4 downtrend. It trades 97.8% below its 200-day average, which is falling.

How far is Enlivex from its 52-week high?

Enlivex closed at $0.20 on Oct 22, 2026, 98.9% below its 52-week high of $18.15. Its 52-week low is $0.20.

How has Enlivex performed over the past year?

As of Oct 22, 2026, Enlivex is down 98.8% over the past year and down 98.2% so far in 2026.

Which sector and industry is Enlivex in?

Enlivex is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.